Summary
Background
Methods
Findings
Interpretation
Funding
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
References
- 1.
Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.J Acquir Immune Defic Syndr. 2006; 41: 194-200
- 2.
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).HIV Med. 2006; 7: 487-503
- 3.
Protease inhibitor-based regimens for HIV therapy: safety and efficacy.J Acquir Immune Defic Syndr. 2007; 45: S5-S13
- 4.
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.JAMA. 2006; 296: 827-843
- 5.
EACS guidelines.(accessed April 23, 2008).
- 6.
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.(accessed April 24, 2008).
- 7.
The role of adherence to antiretroviral therapy in the management of HIV infection.J Acquir Immune Defic Syndr. 2007; 45: S14-S18
- 8.
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).Antivir Ther. 2007; 12: 417-422
- 9.
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.J Infect Dis. 2005; 191: 830-839
- 10.
Carr A, Amin J. Reasons for treatment success with initial ART: an analysis of 2,635 participants in 64 randomized, controlled trials and 14 prospective cohorts. 15th Conference on Retrovirus and Opportunistic Infections; Boston, MA; Feb 3–6, 2008.
- 11.
Class of antiretroviral drugs and the risk of myocardial infarction.N Engl J Med. 2007; 356: 1723-1735
- 12.
Combination antiretroviral therapy and the risk of myocardial infarction.N Engl J Med. 2003; 349: 1993-2003
- 13.
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.HIV Med. 2006; 7: 218-230
- 14.
Atazanavir: a review of its use in the management of HIV infection.Drugs. 2005; 65: 2309-2336
- 15.
Atazanavir: simplicity and convenience in different scenarios.Expert Opin Pharmacother. 2007; 8: 689-700
- 16.
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.Antimicrob Agents Chemother. 2000; 44: 2093-2099
- 17.
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.AIDS. 2006; 20: 711-718
- 18.
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.J Acquir Immune Defic Syndr. 2008; 47: 161-167
- 19.
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.Clin Infect Dis. 2006; 42: 273-280
- 20. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organization, Geneva, Switzerland2006
- 21.
Update of the drug resistance mutations in HIV-1: 2007.Top HIV Med. 2007; 15: 119-125
- 22.
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study.J Acquir Immune Defic Syndr. 2001; 26: 82-92
- 23.
Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments.AIDS Care. 2000; 12: 255-266
- 24.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.Lancet. 2006; 368: 476-482
- 25.
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.AIDS. 2008; 22: 1389-1397
- 26.
Smith K, Fine D, Patel P. Efficacy and safety of abacavir/lamivudine combined to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. 15th Conference on Retrovirus and Opportunistic Infections; Boston, MA; Feb 3–6, 2008.
- 27.
Gathe J, da Silva B, Loutfy M. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects. 15th Conference on Retrovirus and Opportunistic Infections; Boston, MA: Feb 3–6, 2008.
- 28.
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.J Infect Dis. 2004; 190: 280-284
- 29.
Epidemiology of human immunodeficiency virus in the United States.Clin Microbiol Rev. 2007; 20: 478-488
- 30.
Effects of HIV infection and antiretroviral therapy on the heart and vasculature.Circulation. 2008; 118: e36-e40
- 31.
Patient preferences among third agent HIV medications: a US and German perspective.AIDS Care. 2007; 19: 982-988
- 32.
Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study.J Infect Dis. 2008; 197: 1685-1694
- 33.
Stability of antiretroviral regimens in patients with viral suppression.AIDS. 2008; 22: 1039-1046
Article info
Publication history
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Articles
- A king in the CASTLE? Optimum initial HIV protease inhibitor
-
In today's Lancet, Jean-Michel Molina and colleagues describe the 48-week results of the CASTLE study,1 a 96-week, phase III, open-label randomised comparison of ritonavir-boosted atazanavir versus fixed-dose lopinavir–ritonavir, each in combination with the fixed-dose nucleoside reverse-transcriptase inhibitor (NRTI) pairing of tenofovir and emtricitabine. During the past decade, potent antiretroviral therapy has substantially decreased morbidity and improved survival in patients infected with HIV, and the goal of HIV infection as a chronic manageable disease seems achievable.
- Full-Text
-